Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4541-4550

  Hudson, Melissa M ^a   Krasin, Matthew ^a   Link, Michael P ^a   Donaldson, Sarah S ^a   Billups, Catherine ^a   Merchant, Thomas E ^a   Kun, Larry ^a   Billet, Amy L ^a   Kaste, Sue ^a   Tarbell, Nancy J ^a   Howard, Scott ^a   Friedmann, Alison M ^a   Hurwitz, Craig A ^a   Young, Jeffrey A ^a   Marcus, Karen C ^a   Rai, Shesh ^a   Cowan, Traci ^a   Weinstein, Howard J ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG RESPONSE; HODGKIN DISEASE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; ADULT; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; MALE; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; METHOTREXATE; PREDNISONE; PROCARBAZINE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; VINBLASTINE;

EID: 16544364620     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.139     Document Type: Article

References (40)

1. Oberlin O, Leverger G, Pacquement H, et al: Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 10:1602-1608, 1992
2. Schellong G, Bramswig JH, Schwarze EW, et al: An approach to reduce treatment and invasive staging in childhood Hodgkin's disease: The sequence of the German DAL multicenter studies. Bull Cancer 75:41-51, 1988
3. Donaldson SS, Link MP: Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 5:742-749, 1987
4. van Leeuwen FE, Klokman WJ, Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000
5. Schellong G, Riepenhausen M, Creutzig U, et al: Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease: German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 15:2247-2253, 1997
6. Meadows AT, Obringer AC, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477-484, 1989
7. Bramswig JH, Heimes U, Heiermann E, et al: The effects of different cumulative doses of chemotherapy on testicular function: Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65:1298-1302, 1990
8. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208-1215, 1993
9. Green DM, Gingell RL: Regarding cardiac function and morbidity in long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 41:971, 1998
10. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
11. Bossi G, Cerveri I, Volpini E, et al: Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol 8:19-24, 1997(suppl 1)
12. Polliack A: Late therapy-induced cardiac and pulmonary complications in cured patients with Hodgkin's disease treated with conventional combination chemo-radiotherapy. Leuk Lymphoma 15:7-10, 1995 (suppl 1)
13. Hays DM, Ternberg JL, Chen TT, et al: Postsplenectomy sepsis and other complications following staging laparotomy for Hodgkin's disease in childhood. J Pediatr Surg 21:628-632, 1986
14. Green DM, Hyland A, Barcos MP, et al: Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 18:1492-1499, 2000
15. Metayer C, Lynch CF, Clarke EA, et al: Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 18:2435-2443, 2000
16. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003
17. Donaldson SS, Hudson MM, Lamborn KR, et al: VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 20:3081-3087, 2002
18. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
19. Oberlin O: Present and future strategies of treatment in childhood Hodgkin's lymphomas. Ann Oncol 7:73-78, 1996 (suppl 4)
20. Schellong G, Potter R, Bramswig J, et al: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90-The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17:3736-3744, 1999
21. Ruhl U, Albrecht M, Dieckmann K, et al: Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209-1218, 2001
22. Shankar AG, Ashley S, Radford M, et al: Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group. J Clin Oncol 15:2622-2630, 1997
23. Jenkin D, Doyle J, Berry M, et al: Hodgkin's disease in children: Treatment with MOPP and low-dose, extended field irradiation without laparotomy-Late results and toxicity. Med Pediatr Oncol 18:265-272, 1990
24. Weiner MA, Leventhal B, Brecher ML, et al: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 15:2769-2779, 1997
25. Hunger SP, Link MP, Donaldson SS: ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience. J Clin Oncol 12:2160-2166, 1994
26. Hudson MM, Greenwald C, Thompson E, et al: Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11:100-108, 1993
27. Fryer CJ, Hutchinson RJ, Krailo M, et al: Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: A report from the Children's Cancer Study Group. J Clin Oncol 8:1971-1980, 1990
28. Hutchinson RJ, Fryer CJ, Davis PC, et al: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 16:897-906, 1998
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 169
31. Smith RS, Chen Q, Hudson MM, et al: Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 21:2026-2033, 2003
32. Schellong G: The balance between cure and late effects in childhood Hodgkin's lymphoma: The experience of the German-Austrian Study-Group since 1978-German-Austrian Pediatric Hodgkin's Disease Study Group. Ann Oncol 7:67-72, 1996(suppl 4)
33. Sandoval C, Venkateswaran L, Billups C, et al: Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 24:269-273, 2002
34. Friedmann AM, Hudson MM, Weinstein HJ, et al: Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20:3088-3094, 2002
35. Landman-Parker J, Pacquement H, Leblanc T, et al: Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18:1500-1507, 2000
36. Baker KS, Gordon BG, Gross TG, et al: Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 17:825-831, 1999
37. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996
38. Hudson MM, Poquette CA, Lee J, et al: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 16:3592-3600, 1998
39. Vecchi V, Pileri S, Burnelli R, et al: Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age: An Italian (AIEOP) multicenter study on 215 patients. Cancer 72:2049-2057, 1993
40. Weiner MA, Leventhal BG, Marcus R, et al: Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 9:1591-1598, 1991